These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32298002)

  • 41. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population.
    Zambrano-Huailla R; Guedes L; Stefano JT; de Souza AAA; Marciano S; Yvamoto E; Michalczuk MT; Vanni DS; Rodriguez H; Carrilho FJ; Alvares-da-Silva MR; Gadano A; Arrese M; Miranda AL; Oliveira CP
    Ann Hepatol; 2020; 19(6):622-626. PubMed ID: 32919087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis.
    Lee J; Vali Y; Boursier J; Duffin K; Verheij J; Brosnan MJ; Zwinderman K; Anstee QM; Bossuyt PM; Zafarmand MH
    PLoS One; 2020; 15(9):e0238717. PubMed ID: 32915852
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.
    Oh TG; Kim SM; Caussy C; Fu T; Guo J; Bassirian S; Singh S; Madamba EV; Bettencourt R; Richards L; Yu RT; Atkins AR; Huan T; Brenner DA; Sirlin CB; Downes M; Evans RM; Loomba R
    Cell Metab; 2020 Nov; 32(5):878-888.e6. PubMed ID: 32610095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease.
    Koo BK; Um SH; Seo DS; Joo SK; Bae JM; Park JH; Chang MS; Kim JH; Lee J; Jeong WI; Kim W
    Liver Int; 2018 Apr; 38(4):695-705. PubMed ID: 28898507
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.
    Ooi GJ; Mgaieth S; Eslick GD; Burton PR; Kemp WW; Roberts SK; Brown WA
    Obes Rev; 2018 Feb; 19(2):281-294. PubMed ID: 29119725
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004.
    Li L; Huang Q; Yang L; Zhang R; Gao L; Han X; Ji L; Zou X
    Nutrients; 2022 Mar; 14(6):. PubMed ID: 35334881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FEATURES OF EXCRETION OF MELATONIN IN URINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND NON-ALCOHOLIC FATTY LIVER DISEASE WITH MANIFESTATIONS OF FIBROSIS AND ITS RELATIONSHIP WITH CERTAIN METABOLIC AND IMMUNOLOGICAL INDICATORS.
    Zemlianitsyna O; Polozova L; Karachentsev I; Sinaiko V; Kravchun N
    Georgian Med News; 2018 Jan; (274):103-107. PubMed ID: 29461236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
    Adams LA; George J; Bugianesi E; Rossi E; De Boer WB; van der Poorten D; Ching HL; Bulsara M; Jeffrey GP
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1536-43. PubMed ID: 21950746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD.
    Di Mauro S; Scamporrino A; Filippello A; Di Pino A; Scicali R; Malaguarnera R; Purrello F; Piro S
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769333
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease.
    Buzzetti E; Hall A; Ekstedt M; Manuguerra R; Guerrero Misas M; Covelli C; Leandro G; Luong T; Kechagias S; Manesis EK; Pinzani M; Dhillon AP; Tsochatzis EA
    Aliment Pharmacol Ther; 2019 May; 49(9):1214-1222. PubMed ID: 30882933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
    Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
    Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease.
    Nasr P; Hilliges A; Thorelius L; Kechagias S; Ekstedt M
    Scand J Gastroenterol; 2016 Sep; 51(9):1126-32. PubMed ID: 27161854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease.
    Buzzetti E; Petta S; Manuguerra R; Luong TV; Cabibi D; Corradini E; Craxì A; Pinzani M; Tsochatzis E; Pietrangelo A
    Liver Int; 2019 Jul; 39(7):1325-1334. PubMed ID: 30851216
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
    Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Towards an evaluation of alcoholic liver cirrhosis and nonalcoholic fatty liver disease patients with hematological scales.
    Michalak A; Cichoż-Lach H; Guz M; Kozicka J; Cybulski M; Jeleniewicz W; Stepulak A
    World J Gastroenterol; 2020 Dec; 26(47):7538-7549. PubMed ID: 33384553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
    Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease.
    Shin HK; Park JH; Yu JH; Jin YJ; Suh YJ; Lee JW; Kim W;
    Sci Rep; 2021 Sep; 11(1):18004. PubMed ID: 34504179
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD.
    Dioguardi Burgio M; Sartoris R; Beaufrere A; Grégory J; Guiu B; Guillot C; Rautou PE; Castera L; Bouattour M; Paradis V; Vilgrain V; Ronot M
    Eur Radiol; 2022 Mar; 32(3):1781-1791. PubMed ID: 34533606
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
    Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
    [No Abstract]   [Full Text] [Related]  

  • 60. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.